Fig 2.tif (413.8 kB)
Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling - Fig 2
figure
posted on 2018-01-03, 18:39 authored by Martin Grundy, Claire Seedhouse, Thomas Jones, Liban Elmi, Michael Hall, Adam Graham, Nigel Russell, Monica PallisDynamic BH3 profiling assay: delta priming to (A) BAD-BH3 and (B) MS1-BH3 peptides. Delta priming is measured by cytochrome C release after 4 hour drug treatment and additional incubation with the indicated BH3 peptides (BAD-BH3 at 3 μM, MS1-BH3 at 3 μM, PUMA2A control at 100 μM). Values are corrected for cytochrome C release with peptide only as described in the methods. (Mean+/- SD for n = 3).
History
Usage metrics
Categories
Keywords
drugs sensitisingpro-apoptotic anti-leukaemic drug combinationsBH 3-only apoptosis agonists BADMCL -1-targeting MS 1-BH peptideetoposideBAD-BH 3-mediated mitochondrialNOXA target BCL -2anti-leukaemic drugs sensitisingAC 220BCL -2-targeting BAD-BH 3 peptide4 hoursmembrane permeabilisationagents sensitised cellsBH 3BCL -2DNAinhibitors pladienolide BFLT 3 inhibitor AC 220cytochrome C releasepladienolide Bcompounds ABT -199BCL -2 inhibitors ABT -199BET domain inhibitor JQ 1downregulate BCL -2BCL -2 antagonism
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC